Vural, SelahattinAva, SedatPolat, Ferhat BaverKeklikci, Ugur2025-02-222025-02-2220251579-58532255-0569https://doi.org/10.3306/AJHS.2025.40.01.40https://hdl.handle.net/11468/29575Background and objective: This study aims to compare the effects of two different anti-VEGF drugs, aflibercept and ranibizumab, on OCT findings in patients with AMD. Materials and methods: We reviewed the medical records of patients diagnosed with wet type AMD between 2013-2020, who were treated with intravitreal ranibizumab or aflibercept, and had a minimum follow-up period of six months. Results: Aflibercept was injected into 50 eyes and ranibizumab was injected into 53 eyes. In best corrected visual acuity (BCVA) measurements, aflibercept was found to be superior especially at 1 month (p=0.003), and no difference was found in BCVA at 6 months (p=0.233). A negative correlation was found between BCVA measurements and SFC measurements at 1 month (r=-0.322, p=0.001). In the comparison of aflibercept and ranibizumab at 6 months; Aflibercept was found to be more effective than ranibizumab in reducing CFT (p=0.014). However, no statistically significant difference was found between aflibercept and ranibizumab in horizontal PED, vertical PED, HRD, IRC, SRF, ERM, ELM, ISOS, and CNVM measurements (p=0.119; p=0.220; p=0.167; p=0.531; p=0.351; p=0.844; p=0.768; p=0.944; p=0.703, respectively). Conclusions: Intravitreal aflibercept and ranibizumab injections in wet AMD patients were found to have similar effects on other OCT findings except for CFT. Studies with long follow-up and large series on this subject will provide more information.eninfo:eu-repo/semantics/closedAccessAge-related macular degenerationoptical coherence tomographyafliberceptranibizumabchoroidal neovascular membraneAge-related macular degenerationoptical coherence tomographyafliberceptranibizumabchoroidal neovascular membraneArticle401WOS:00139789600000510.3306/AJHS.2025.40.01.40N/A